Company Overview of Ardelyx, Inc.
Ardelyx, Inc. discovers, develops, and commercializes minimally-systemic small molecule therapeutics for the gastrointestinal (GI) tract to treat cardio-renal, GI, and metabolic diseases. Its lead product candidate is tenapanor, a small molecule NHE3 inhibitor, which has completed Phase 2b clinical trial for the treatment of patients with constipation-predominant irritable bowel syndrome and hyperphosphatemic patients with chronic kidney disease on dialysis, as well as Phase 2a clinical trial in patients with late-stage chronic kidney disease. The company’s discovery and lead development programs that are in research phase include RDX002 NaP2b inhibitor for hyperphosphatemia; RDX009 TGR5 ago...
34175 Ardenwood Boulevard
Fremont, CA 94555
Founded in 2007
Key Executives for Ardelyx, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $416.3K
Senior Vice President of Drug Development
Total Annual Compensation: $277.5K
Compensation as of Fiscal Year 2013.
Ardelyx, Inc. Key Developments
Ardelyx, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 09:30 AM
Feb 26 15
Ardelyx, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 09:30 AM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Speakers: Michael G. Raab, Chief Executive Officer, President and Director.
Ardelyx, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014
Feb 25 15
Ardelyx, Inc. announced unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company announced total revenue of $6,338,000 compared to $8,488,000 for the same period a year ago. Loss from operations was $3,932,000 compared to $718,000 for the same period a year ago. Net loss and comprehensive loss was $3,970,000 compared to $4,269,000 for the same period a year ago. Basic and diluted net loss per share was $0.21 compared to $3.53 for the same period a year ago.
For the full year, the company announced total revenue of $31,623,000 compared to $28,928,000 for the same period a year ago. Loss from operations was $1,564,000 compared to $2,865,000 for the same period a year ago. Net loss and comprehensive loss was $3,214,000 compared to $6,564,000 for the same period a year ago. Basic and diluted net loss per share was $0.31 compared to $5.82 for the same period a year ago. Increase in revenue for both the full year and the fourth quarter was primarily due to the amortization of deferred revenue from a $15.0 million development milestone payment that the company received in December 2013 and a milestone payment of $25.0 million that the company received in May 2014.
Ardelyx, Inc. to Report Q4, 2014 Results on Feb 25, 2015
Feb 18 15
Ardelyx, Inc. announced that they will report Q4, 2014 results at 1:01 PM, GMT Standard Time on Feb 25, 2015
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|